cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1754Research ArticleПРАКТИЧЕСКАЯ КАРДИОЛОГИЯСовременные позиции β-адреноблокаторов в терапии ишемической болезни сердца. В помощь практическому врачуCurrent position of beta-adrenoblockers in coronary heart disease management: information for cliniciansЛибовИ. А.LibovI. A.

Доцент кафедры терапии и подростковой медицины.

Москва.

Тел.: (499) 728-81-97

 

igor.libov@mail.ruМоисееваЮ. Н.MoiseevaYu. N.

Врач-кардиолог.

Москва.

 

ГайнуллинаА. Р.GaynullinaA. R.

Клинический ординатор кафедры.

Москва.

Городская клиническая больница им. С.П. БоткинаS.P. Botkin Moscow City Clinical HospitalГОУ ДПО Российская медицинская академия последипломного образованияRussian Medical Academy of Post-Diploma Education200920042009826871Copyright © Либов И.А., Моисеева Ю.Н., Гайнуллина А.Р., 20092009Либов И.А., Моисеева Ю.Н., Гайнуллина А.Р.Libov I.A., Moiseeva Y.N., Gaynullina A.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1754

β-адреноблокаторы (β-АБ) - одни из наиболее часто назначаемых медикаментозных средств при лечении ИБС. Обсуждается выбор β-АБ и место препаратов этого класса в оптимальных схемах лечения больных ИБС. 

Beta-adrenoblockers (ВАВ) are widely used in coronary heart disease (CHD) management. The choice of specific ВАВ and their place in optimal schemes for CHD treatment are discussed. 

ишемическая болезнь сердцаβ-адреноблокаторыантиаритмический эффектcoronary heart diseasebeta-adrenoblockersantiarrhythmic effectReferencesHedblad В, Wikstrand Г, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the beta-blocker cholesterol-lowering asymptomatis plaque study. Circulation 2001; 103: 1721-6.Hedblad В, Wikstrand Г, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the beta-blocker cholesterol-lowering asymptomatis plaque study. Circulation 2001; 103: 1721-6.Wiklund О, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol оп carotid intima-media thickness in patients with hypercholesterolemia. А 3-year randomized study. Stroke 2002; 33: 572- 7.Wiklund О, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol оп carotid intima-media thickness in patients with hypercholesterolemia. А 3-year randomized study. Stroke 2002; 33: 572- 7.Беленков Ю.Н., Мареев В.Ю. Как мы диагностируем и лечим сердечную недостаточность в реальной клинической практике в начале XXI века? Результаты исследования IMPROVEMENТ HF. Cons med 2001; 3(2): 65-72.Беленков Ю.Н., Мареев В.Ю. Как мы диагностируем и лечим сердечную недостаточность в реальной клинической практике в начале XXI века? Результаты исследования IMPROVEMENТ HF. Cons med 2001; 3(2): 65-72.Kjekshus Г, Apetrei Е, Barrios V, et al. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248-61.Kjekshus Г, Apetrei Е, Barrios V, et al. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248-61.GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): а randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): а randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.Poole-Wtlson РА, Swedberg К, Cleland JGF, et al. Comparison of carvedilol and metoprolol оп clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial. Lancet 2003; 362: 7-13.Poole-Wtlson РА, Swedberg К, Cleland JGF, et al. Comparison of carvedilol and metoprolol оп clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial. Lancet 2003; 362: 7-13.Metoprolol CR/XL Randomized Intervention Study in Heart Failure. Hjalmarson А, Goldstein S, Fagerberg В, et al. Effects of controlled-release metorpolol оп total mortality, hospitalizations, and well-being in patients with heart failure. JАМА 2000; 283: 1295-302.Metoprolol CR/XL Randomized Intervention Study in Heart Failure. Hjalmarson А, Goldstein S, Fagerberg В, et al. Effects of controlled-release metorpolol оп total mortality, hospitalizations, and well-being in patients with heart failure. JАМА 2000; 283: 1295-302.Kuehlkamp V, Schirdewan А, Stangl К, et al. Use of metoprolol CR to maintain sinus rhythm after conversion from persistent atrial fibrillation. Arandomized douЫe-blind placebo-controlled study. Circulation 1998; 98(Suppl 1): 1-633.Kuehlkamp V, Schirdewan А, Stangl К, et al. Use of metoprolol CR to maintain sinus rhythm after conversion from persistent atrial fibrillation. Arandomized douЫe-blind placebo-controlled study. Circulation 1998; 98(Suppl 1): 1-633.Olsson G, Rehnkvist N. Reduction in nonfatal reinfarctions in patients with а history of hypertension bу chronic postinfarction treatment with metoprolol. Acta Med Scand 1986; 220: 33-8.Olsson G, Rehnkvist N. Reduction in nonfatal reinfarctions in patients with а history of hypertension bу chronic postinfarction treatment with metoprolol. Acta Med Scand 1986; 220: 33-8.Navaпo-Lopez F, Cosin J, Marrugat JБ, et al. Comparison of the effects of amiodarone versus metoprolol оn the frequency of ventricular arrhythmias and оn mortality after acute myocardial infarction. Аm J Cardiol 1993; 72: 1243-8.Navaпo-Lopez F, Cosin J, Marrugat JБ, et al. Comparison of the effects of amiodarone versus metoprolol оn the frequency of ventricular arrhythmias and оn mortality after acute myocardial infarction. Аm J Cardiol 1993; 72: 1243-8.

The authors declare that there are no conflicts of interest present.